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Background and objectives:While the literature supports the idea that multiple sclerosis (MS) and migraine are
related, the exact mechanism(s) of this association is not well understood. Observations of increased contrast
enhancing (CE) lesion activity in individual MS patients suffering from migraine prompted us to determine a
relationship between migraine and MRI outcomes in a large cohort of MS patients.
Methods:We included 509MS and 64 clinically isolated syndrome (CIS) patients and 251 age- and sex-matched
healthy individuals (HIs)who obtained3 TMRI andwere assessed for history ofmigraine. Number and volumeof
T2, T1 and CE lesions and brain volumemeasureswere determined. TheMRIﬁndingswere analyzed adjusting for
key covariates and correcting for multiple comparisons.
Results:More MS (22.2%) and CIS (17.2%) patients had migraine, compared to HIs (14.6%, p = 0.067). More MS
patients with migraine presented with CE lesions compared to those without (35.4% vs. 23.7%, p = 0.013). MS
migraine patients had signiﬁcantly increased number (p = 0.019) and volume (p = 0.022) of CE lesions com-
pared to those without. In the regression analysis, MS migraine patients had an increased number of CE lesions
(B = 1.242, p = 0.001), speciﬁcally those with relapsing–remitting disease course (B = 1.377, p = 0.001).
No signiﬁcant association of other MRI measures and migraine was found in MS and CIS patients or in HIs.
Conclusions: Our ﬁndings suggest an increased inﬂammatory pathobiology in MS patients with migraine head-
aches requiring possibly more frequent MRIs and also more efﬁcient anti-inﬂammatory treatment.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multiple sclerosis (MS) is an autoimmune disease of the central ner-
vous system characterized by demyelination and axonal loss. Signs and
symptoms can vary widely throughout the disease course. While sensi-
tive, optic and motor symptoms predominate, other symptomatology
can include urinary tract and bowel dysfunction, pain, fatigue, cognitive
dysfunction and mood disorders (Samkoff and Goodman, 2011).
Several case–control studies have established a higher rate of head-
ache inMSpopulation compared to the healthy individuals (HIs) (Kister
et al., 2010; Nicoletti et al., 2008; Vacca et al., 2007; Watkins and Espir,erms of the Creative Commons
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. This is an open access article under1969; Zorzon et al., 2003). The potential link between MS andmigraine
has been hypothesized for over 40 years (Elliott, 2007; Watkins and
Espir, 1969). It has been recently shown that MS patients had a three-
fold higher frequency of migraine compared to the HIs (Kister et al.,
2010). Another most recent meta-analysis found that migraine was
more common in 1864 MS patients compared to the 261,563 control
subjects, with an odds ratio of 2.6, however there was a heterogeneity
between the examined studies (Pakpoor et al., 2012). On the contrary,
another German study did not ﬁnd a higher prevalence of headache or
migraine in 491 MS patients compared to 447 controls (Putzki et al.,
2009).
While the literature supports the idea that MS and migraine are re-
lated, the exactmechanism(s) of this association is not well understood
(Kister et al., 2010; Nicoletti et al., 2008; Pakpoor et al., 2012; Vacca
et al., 2007; Watkins and Espir, 1969; Zorzon et al., 2003). Is migraine
simply a comorbidity of MS? Can it signal the onset of MS? If so, what
is the underlying pathology? Is it increased frequency related to use of
disease-modifying treatment (DMT)? These questions have important
implications for diagnosis and treatment of MS and need to be
addressed in the future studies. Several studies investigated frequency
of migraine in relation to the clinical course of MS and determinedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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remitting (RR) MS, whereas the tension-type headache is more frequent
in patientswith chronic progressiveMS (D3Amico et al., 2004; Ergun et al.,
2009; Moisset et al., 2013; Villani et al., 2008). A recent case report illus-
trated a young woman whose initial presentation was that of status
migrainosus, after which she developed MS within 2 years (Alroughani
et al., 2015). The term radiologically isolated syndrome (RIS) has been re-
cently proposed to describe patients with atypical symptoms of MS who
present with MRI features suggestive of underlying demyelinating pa-
thology (Okuda et al., 2009). One of the most common complaints in
RIS subjects which led to performance of the MRI examination was
migraine type headache (Lebrun et al., 2008; Okuda et al., 2009). This
suggests that migraine can be prominent symptom at early onset of the
disease, in addition to have increased comorbidity frequency in RRMS
patients.
It has been recently reported in a case study that a patient who had a
history of migraine, experienced worsening of migraine-headache symp-
toms as the initial manifestation of MS, and showed concomitant asymp-
tomatic contrast enhancing (CE) lesions on T1-weighted MRI after
gadolinium (Gd) contrast injection (Lin et al., 2013). This case report
raises question, as to the role of CE lesions in the presentation ofmigraine
in MS patients. Our own clinical routine observations prompted us to in-
vestigate whether the number and volume of CE lesions are associated to
increased frequency of migraine in MS patients. In addition, we aimed to
determine if there is relationship between migraine and the presence
of other lesion and global and tissue speciﬁc brain volume measures in
patients with MS.2. Methods
2.1. Subjects
This study used data from an ongoing prospective study of cardio-
vascular, genetic and environmental risk factors in MS that enrolled
over 1000 patients with clinically isolated syndrome (CIS), MS, other
neurological diseases and HIs (Kappus et al., 2015; O3Connor et al.,
2012; Zivadinov et al., 2011). The inclusion criteria for this sub-study
of migraine in MS were as follows: a) age 18–75 years old, b) having
CIS or MS, or being HI and c) MRI examination performed at the time
of the clinical visit (±30 days) with standardized 3 T MRI protocol.
The exclusion criteria were as follows: a) the presence of a relapse or
steroid treatment within 30 days preceding study entry for MS and
CIS patients, b) presence of acute headache attack at the time of MRI,
c) pre-existing medical conditions known to be associated with brain
pathology and d) pregnancy.
Subjects were assessed with structured environmental question-
naire followed by physical and neurological examination. Migraine
data were collected from participants in an in-person interview by a
trained interviewer, as well as by examination of the patients3 medical
records (Dolic et al., 2011). Migrainewas deﬁned according to the Inter-
national Classiﬁcation of Headache Disorders (ICHD-2) guidelines
(Headache Classiﬁcation Subcommittee of the International Headache
Society, 2004). Subjects who had at least 5 headache attacks in the
past that lasted 4–72 h, had at least two of the following characteristics
(unilateral location, pulsating quality, moderate or severe pain intensi-
ty, aggravation by or causing avoidance of routine physical activity),
presence of nausea/vomiting, andwere not better accounted by another
disorder were classiﬁed as migraine headache.
HIs were recruited from hospital personnel, spouses of MS patients
or were respondents of local advertisements. By deﬁnition HIs were re-
quired to have a normal neurological examination and have a normal
MRI health screen. Race/ethnicity was determined according to the US
Census Bureau deﬁnitions.
The study protocol was approved by the local Institutional Review
Board and all participants gave their written informed consent.2.2. MRI acquisition and analysis
All subjects were examined on a 3T GE Signa Excite HD 12.0 Twin
Speed 8-channel scanner (General Electric, Milwaukee, WI). MRI se-
quences included the axial dual fast spin-echo (FSE) T2/PD-weighted
image (WI), 3D-spoiled-gradient recalled (SPGR) T1-WI, spin echo (SE)
T1-WI pre- and post-contrast, and ﬂuid attenuated inversion recovery
(FLAIR) scans. Pulse sequence characteristics for 3 TMRI were as follows:
all scans were acquired with a 256 × 256 matrix and a 25.6 cm ﬁeld of
view (FOV) for an in-plane resolution of 1 × 1 mm2 with a phase FOV
of 75% and one average. Sequence speciﬁc parameters were as
follows: for the T2/PD-WI: 3-mm-thick slices with no gap, TE1/TE2/
TR = 12/95/3000 ms, echo train length = 14, ﬂip angle = 90°; for the
FLAIR scans, 3-mm thick slices with no gap, TE/TI/TR = 120/2100/
8500 ms, ﬂip angle = 90°; for 3D T1-WI, 1-mm thick slices with no gap,
TE/TI/TR = 2.8/900/5.9 ms, ﬂip angle = 10° and for SE T1-WI, 3-mm
thick slices with no gap, TE/TR = 16/600 ms, ﬂip angle = 90°. The SE
T1-WI sequence was obtained after injection of a single dose intravenous
bolus (0.1mmol/kg gadolinium-DTPA) 5min after administration of con-
trast agent only in MS and CIS patients (Kappus et al., 2015; Zivadinov
et al., 2012).
The following MRI measures were collected: CE, T1 and T2 lesion
number and lesion volumes (LVs), assessed by a semi-automated edge
detection contouring/thresholding technique, as previously reported
(Zivadinov et al., 2012). Measures of brain atrophy included normalized
brain volume, normalized gray matter (GM) volume, normalized white
matter (WM) volume, normalized cortical volume and normalized lat-
eral ventricle volume (Kappus et al., 2015; Zivadinov et al., 2012),
assessed by the SIENAX 2.6 cross-sectional software tool (Smith et al.,
2002).2.3. Statistical analysis
All data were analyzed using Statistical Package for Social Science
(SPSS), version 20.0 (IBM, Armonk, NY). The data were analyzed
both by disease group (MS, CIS and HIs) and by MS disease subtype
(RR, SP and PP). Differences in demographic and clinical characteris-
tics between subjects with and without migraine were analyzed
using chi-square test, Mann–Whitney rank sum test and analysis of
variance (ANOVA), as appropriate. In the analysis of covariance
(ANCOVA), MRI outcomes were input as the dependent variables,
and disease group or MS disease subtype, as the grouping measure
with age, gender and DMT status selected as covariates. Given the co-
linearity between age and disease duration, the latter was not used
as covariate.
Additionally, the data were also analyzed using a negative bino-
mial regression given the non-normally distributed lesion data. The
inputs into the model included the number of CELs as the dependent
measure and migraine status, age, gender and DMT status as the
independent variables. Regression analysis was applied to both the
disease groups and MS subtypes. The Benjamini–Hochberg
correction was used to control the false discovery rate and
p-values b 0.05 were considered signiﬁcant using two-tailed testing
(Benjamini et al., 2001).
3. Results
3.1. Demographic and clinical characteristics
A total of 826 subjects who fulﬁlled inclusion and exclusion criteria
were selected for this substudy of migraine and MRI. These included
320 patients with RRMS, 124 patients with secondary-progressive (SP)
MS, 36 patients with primary-progressive (PP) MS, 64 patients with
CIS and 251 HIs. As expected MS patients had higher age, longer disease
duration and more advanced disability compared to CIS patients.
Table 1
Characteristics of subjects with and without migraine in patients with multiple sclerosis and clinically isolated syndrome, and in healthy individuals.
HIs
(n = 251)
MS
(n = 509)
CIS
(n = 64)
W/o migraine
(n = 214)
Migraine
(n = 37)
p-Value W/o migraine
(n = 396)
Migraine
(n = 113)
p-Value W/o migraine
(n = 53)
Migraine
(n = 11)
p-Value
Female, n (%) 136 (63.6) 28 (75.7) 0.135 266 (67.2) 95 (84.1) 0.01 38 (71.7) 10 (90.1) 0.181
Age in years, mean (SD) 43.0 (17.4) 43.6 (13.9) 0.852 46.9 (12.4) 42.4 (13.0) 0.001 39.9 (11.3) 38.3 (9.9) 0.001
Age at onset in years, mean (SD) NA NA NA 32 (10.7) 29.8 (10.5) 0.066 36.0 (11.1) 31.9 (10.5) 0.266
Disease duration in years, mean (SD) NA NA NA 15 (10.7) 12.4 (9.6) 0.024 1.3 (2.1) 1.4 (2.2) 0.115
BMI, mean (SD) 26.8 (5.5) 26.9 (5.5) 0.95 26.7 (5.5) 26.5 (5.9) 0.745 27.2 (6) 26.5 (5.5) 0.734
Presence of DMT, n (%) NA NA NA 284 (71.7) 83 (73.5) 0.884 26 (49.1) 4 (36.3) 0.634
Interferon-beta 1a 140 (49.3) 34 (41) 20 (76.9) 3 (75)
Glatiramer acetate 73 (25.7) 27 (32.5) 6 (23.1) 1 (25)
Natalizumab 56 (19.7) 18 (21.7) 0 (0) 0 (0)
Mycophenolate mofetil 6 (2.1) 1 (1.2) 0 (0) 0 (0)
Intravenous immunoglobulin 5 (1.8) 2 (2.4) 0 (0) 0 (0)
Azathioprine 3 (1.1) 1 (1.2) 0 (0) 0 (0)
Mitoxantrone 1 (0.4) 0 (0) 0 (0) 0 (0)
EDSS, mean (IQR) NA NA NA 3.6 (2.2) 3.2 (1.8) 0.082 1.3 (.7) 1.9 (1.7) 0.092
Race, n (%) 0.168 0.337
White 183 (85.5) 33 (89.2) 373 (94.2) 103 (91.2) 48 (90.5) 11 (100) 0.771
Hispanic/Latino 2 (0.9) 1 (2.7) 4 (1.0) 4 (3.5) 2 (3.8) 0 (0)
Black/African/American 16 (7.5) 2 (5.4) 15 (3.8) 5 (4.4) 2 (3.8) 0 (0)
Asian 8 (3.7) 0 (0) 2 (0.5) 0 (0) 1 (1.9) 0 (0)
American Indian/Alaska native 0 (0) 1 (2.7) 0 (0) 0 (0) 0 (0) 0 (0)
Other 5 (2.3) 0 (0) 2 (0.5) 1 (0.9) 0 (0) 0 (0)
HIs—healthy individuals; MS—multiple sclerosis; CIS—clinically isolated syndrome; SD—standard deviation; EDSS—Expanded Disability Status Scale; DMT—disease modifying therapy;
NA—not available; BMI—body mass index; IQR— interquartile range.
The comparison between the migraine and non-migraine subjects was performed using chi-square test, Mann–Whitney rank sum test and one-way analysis of variance. p-Values b 0.05
were considered signiﬁcant (highlighted in bold).
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the subjects with or withoutmigraine. In theMS group therewas sig-
niﬁcantly more females with migraine (p = 0.01). The age of the MS
patients with migraine was younger (p = 0.001) and disease dura-
tion was shorter (p = 0.024). In the MS disease subtype analyses,Table 2
Characteristics of subjects with and without migraine in patients with relapsing–remitting, sec
RRMS
(n = 320)
SP
(n
W/o migraine
(n = 241)
Migraine
(n = 79)
p-Value W
(n
Female, n (%) 159 (78.8) 68 (86.1) 0.001 77
Age in years, mean (SD) 44.6 (10.3) 42.2 (11.4) 0.081 54
Age at onset in years, mean (SD) 32.3 (9.2) 30.2 (9.4) 0.082 32
Disease duration in years, mean (SD) 12.4 (8.9) 11.4 (8.7) 0.401 22
BMI, mean (SD) 27.5 (5.6) 27.0 (6) 0.555 25
Presence of DMT, n (%) 204 (84.6) 60 (75.9) 0.579 72
Interferon-beta 1a 101 (49.5) 24 (40) 40
Glatiramer acetate 51 (25) 21 (35) 14
Natalizumab 45 (22.1) 14 (23.3) 12
Mycophenolate mofetil 3 (1.5) 0 (0) 3 (
Intravenous immunoglobulin 3 (1.5) 1 (1.7) 1 (
Azathioprine 0 (0) 0 (0) 2 (
Mitoxantrone 1 (0.5) 0 (0) 0 (
EDSS, mean (IQR) 2.6 (1.5) 2.6 (1.4) 0.884 5.6
Race, n (%) 0.385
White 225 (93.4) 70 (88.6) 10
Hispanic/Latino 3 (1.2) 3 (3.8) 1 (
Black/African/American 10 (4.1) 5 (6.3) 2 (
Asian 2 (0.8) 0 0
American Indian/Alaska native 0 (0) 0 0
Other 1 (0.4) 1 (1.3) 1 (
MS—multiple sclerosis; RRMS—relapsing–remitting; SPMS—secondary-progressive; PPMS—
DMT—disease modifying therapy; NA—not available; BMI—body mass index; IQR—interquartil
The comparison between the migraine and non-migraine groups was performed using chi-squ
were considered signiﬁcant (highlighted in bold).the SPMS patients with migraine were younger (p = 0.015), while
the PPMS patients with migraine were younger (p = 0.032) and
had lower disease duration (p = 0.039). The CIS patients with mi-
graine were younger compared to those without migraine (p =
0.001).ondary-progressive and primary-progressive multiple sclerosis.
MS
= 124)
PPMS
(n = 36)
/o migraine
= 104)
Migraine
(n = 20)
p-Value W/o migraine
(n=30)
Migraine
(n = 6)
p-Value
(74) 18 (90) 0.122 17 (56.7) 3 (50) 0.764
.7 (7.5) 49.9 (10.6) 0.015 56.0 (6.9) 49.3 (4.7) 0.032
.4 (11.1) 29.2 (9.9) 0.22 37.9 (10.8) 42.4 (6) 0.374
.4 (10.9) 20.7 (9.8) 0.527 18.1 (11.5) 6.8 (4.5) 0.039
.8 (5) 24.7 (5.7) 0.376 26.1 (4.2) 26.0 (5.6) 0.954
(69.2) 15 (75) 0.831 13 (43.3) 3 (50) 0.85
(55.6) 6 (40) 5 (38.5) 1 (33.3) 5
(19.4) 5 (33.3) 5 (38.5) 2 (66.7)
(16.7) 2 (13.3) 0 (0) 0 (0)
4.2) 0 (0) 1 (7.7) 0 (0)
1.4) 1 (6.7) 1 (7.7) 0 (0)
2.8) 1 (6.7) 1 (7.7) 0 (0)
0) 0 (0) 0 (0) 0 (0)
(1.5) 5.2 (1.9) 0.25 5.7 (1.9) 4.8 (1.2) 0.298
0.851 0.071
0 (96.1) 20 (100) 29 (96.7) 5 (83.3)
1.0) 0 (0) 0 (0) 1 (16.7)
1.9) 0 (0) 1 (3.3) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
1.0) 0 (0) 0 (0) 0 (0)
primary-progressive; SD—standard deviation; EDSS—Expanded Disability Status Scale;
e range.
are test, Mann–Whitney rank sum test and one-way analysis of variance. p-Values b 0.05
Table 3
Within study group MRI comparisons between subjects with and without migraine.
HIs
(n = 251)
MS
(n = 509)
CIS
(n = 64)
W/o migraine
(n = 214)
Migraine
(n = 37)
p-Value W/o migraine
(n = 396)
Migraine
(n = 113)
p-Value W/o migraine
(n = 53)
Migraine
(n = 11)
p-Value
Presence of CE lesions NA NA NA 94 (23.7) 40 (35.4) 0.013 9 (17) 2 (18.2) 0.923
Number of CE lesions NA NA NA 0.21 (0.74) 0.91 (4.36) 0.019 0.45 (1.25) 0.10 (0.32) 0.380
CE-LV NA NA NA 31.2 (134.4) 125.3 (572.6) 0.022 65.8 (196.5) 5.4 (17.1) 0.326
Number of T2 lesions 2.7 (6.82) 2.03 (4.5) 0.505 29 (20) 27.8 (19.8) 0.401 22.2 (25.8) 11 (6.9) 0.170
T2-LV 277.1 (1200) 113.5 (241.1) 0.402 13,901.7 (16,530.2) 13,546.2 (15,966.2) 0.829 4406.7 (6111.7) 1960.9 (1794.3) 0.183
Number of T1 lesions NA NA NA 11.21 (11.52) 10.12 (12.33) 0.412 4.14 (7.83) 2.70 (4.88) 0.469
T1-LV NA NA NA 3021.6 (5528.6) 3082.4 (7479.1) 0.832 423.6 (731.8) 369.3 (957.9) 0.706
NBV 1533.8 (95.3) 1551.9 (83) 0.089 1474.5 (99.1) 1484.9 (95.6) 0.278 1543.4 (63.7) 1580 (81.3) 0.157
NGMV 780.2 (67.2) 789.9 (52.7) 0.191 734.4 (71.9) 747.4 (68.2) 0.651 784 (49) 802.3 (59.9) 0.444
NWMV 753.6 (44.1) 762.1 (44.1) 0.156 740.1 (66.8) 737.5 (65) 0.332 759.4 (44.1) 777.7 (70.6) 0.278
NLVV 34.3 (15.5) 30.2 (9.2) 0.107 49.6 (22.6) 46 (22.1) 0.954 35.2 (12.7) 33.9 (19.2) 0.999
NCV 636.1 (57.4) 644.3 (46.3) 0.231 594.3 (60.7) 607.1 (56.9) 0.819 633.4 (40.5) 658.6 (47.7) 0.115
HIs—healthy individuals; MS—multiple sclerosis; CIS—clinically isolated syndrome; CE—contrast enhancing; LV—lesion volume; NA—not available; NBV—normalized brain volume;
NGMV—normalized gray matter volume; NWMV—normalized white matter volume; NLVV—normalized lateral ventricular volume; NCV—normalized neocortical volume.
All data are presented asmean and standard deviations. The presence of CE is reported as the number and percentage. Volumetric measures are presented in cubicmillimeters (mm3) for
LV and in cubic centimeters (cm3) for brain volumes.
The comparison between HIs, MS and CIS groups was performed using analysis of covariance with age, gender and disease-modifying treatment, as covariates. p-Values b 0.05 were con-
sidered signiﬁcant (highlighted in bold) after correction for multiple comparisons.
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Hundred and thirteen (22.2%)MSpatients, 11 (17.2%) of CIS patients
and 37 (14.7%) of HIs had migraine (p = 0.067). In the MS disease
subtype analyses, patients with RRMS had the highest rate of migraine
(24.7%), followed by PPMS (16.7%) and SPMS (16.1%) (p = 0.108).
3.3. MRI differences in subjects with and without migraine
Table 3 and Fig. 1 show within disease group differences in subjects
with and without migraine. More MS patients with migraine presented
with CE lesions compared to thosewithout (35.4% vs. 23.7%, p=0.013).
The mean number of CE lesions in MS patients with migraine was in-
creased respect to those without (0.91 vs. 0.21, p = 0.019). The mean
CE-LV was also increased in subjects with migraine respect to those
without (125.3 vs. 31.2 mm3, p = 0.022). No other MRI lesion and
brain volume MRI outcome differences were found in subjects with
and without migraine within speciﬁc disease groups.
Table 4 shows within MS disease subtype study MRI outcome dif-
ferences in subjects with and without migraine. More RRMS patients
with migraine presented with CE lesions compared to those without
(41.8% vs. 28.2%, p = 0.035). RRMS patients with migraine had in-
creased mean number of CE lesions (1.19 vs. 0.27, p = 0.023) and
CE-LV (164.4 vs. 41.1 mm3, p = 0.02) compared to those without.
No other MRI lesion and brain volume outcome differences were
found in subjects with and without migraine within MS disease
subtypes.
3.4. Regression analysis
Given the non-normally distributed lesion data, we used negative bi-
nomial regression to validate the ANCOVA results. MS patients withmi-
graine had increased number of CE lesions (B = 1.242, p = 0.001), but
not CE-LV (B= 1.320, p= 0.133) compared to thosewithout migraine.
RRMS patients with migraine had increased number of CE lesions (B=
1.377, p = 0.001), but not CE-LV (B = 1.490, p = 0.098) compared to
those without migraine.
4. Discussion
This is the largest case–control study to date that investigated the as-
sociation between migraine and MRI outcomes in MS patients. Wefound that there is an increased frequency of CE lesions in MS patients
with migraine, speciﬁcally within the RRMS disease subtype. Given
that our clinical/MRI assessments were performed on MS patients
with a stable clinical status and in absence of acute headache attack
prior to MRI examination, the current ﬁndings suggest that having mi-
graine comorbiditymay increase level of blood–brain-barrier (BBB) dis-
ruption in RRMS patients.
Presence of CE lesions is an indicator of inﬂammation and breakdown
of the BBB, and MRI hallmark for diagnosis and monitoring of MS.
Migraine is a disorder characterized by a strong vascular component
in which vasoconstriction is followed by vasodilation, mediated by un-
derlying inﬂammatory cytokines and/or neuropeptides (Silberstein,
2004). On the other hand, cardiovascular risk factors, including smoking,
hypertension, hyperlipidemia, overweight/obesity, diabetes and heart
disease are associated with MS (Kappus et al., 2015; Karmon et al.,
2012). The pathophysiology of migraine is complex and variety of medi-
ating mechanisms have been proposed including changes in levels of
magnesium, calcium and glutamate, as well 5-HT, which stimulates
the release of substance P and calcitonin gene related peptide
(Silberstein, 2004).While our study did not assess any one of these fac-
tors, our ﬁndings do suggest that alterations of the BBB may compro-
mise the microenvironmental vascular regulation. Indeed, previous
studies suggested that the pathogenesis ofmigraine includes an inﬂam-
matory component (Longoni and Ferrarese, 2006). The inﬂammation of
the meninges is an accepted component of the migraine process with
release of vasogenic substances such as calcitonin gene-related peptide,
substance P, neurokinin A, vasoactive intestinal peptide, and nitric
oxide (Buzzi et al., 1991). In the last decade, it has been established
that highly inﬂammatory cortical demyelination is also present and
common in early MS, topographically associated with prominent men-
ingeal inﬂammation and may even precede the appearance of classic
WM plaques in some MS patients (Lucchinetti et al., 2011). Therefore,
future work should explore the association betweenmeningeal inﬂam-
mation and BBB in MS patients with and without migraine.
In line with previous studies, we found that migraine is present at
higher rates in patients with RRMS, compared to those with chronic
progressive MS disease subtype (D3Amico et al., 2004; Ergun et al.,
2009; Moisset et al., 2013; Villani et al., 2008). These ﬁndings are of in-
terest in the context of our results that showed that only RRMS patients
had increased number and volume of CE lesions. This may suggest that
increased inﬂammatory component of the disease, usually present in
earlier disease stages, may contribute to the development of migraine.
Fig. 1. Representative MRI images of a 32 years old female relapsing–remitting multiple sclerosis patient with disease duration of 11 and 9 years history of migraine. On the left are
displayed T1-weighted spin echo post-contrast images (after 5 min delay), in the middle are shown T1-weighted spin echo pre-contrast images and on the right are displayed represen-
tative ﬂuid attenuation inversion recovery images. There are 3 visible contrast enhancing lesions (white arrows) in different brain lobes and hemispheres.
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the temporal relationship between onset of migraine andMS onset. The
fact that no association of CE lesions and migraine was found in CIS pa-
tients and that frequency of migraine was higher in RRMS vs. CIS in the
present study, indicates that migraine may be, at least in part, a comor-
bidity of MS disease process which is related to more severe BBB dam-
age. A meta-analysis study demonstrated that the number of CE
lesions over the ﬁrst 6 months of follow-up increased the relative risk
of relapse occurrence in the subsequent year (Kappos et al., 1999). It
has been shown that patients in the relapsing phase have signiﬁcantly
more migraine attacks than those in the remitting phase (Ergun et al.,
2009). Indeed, there were no differences in CE lesions in patients with
SP and PPMSwith andwithoutmigraine in the present study. However,
it has to be underlined that PPMS patient did not present any CE lesions.While the present study was cross-sectional in design, it will be inter-
esting to monitor the occurrence of CE lesions and migraine attacks in
future longitudinal prospective studies using serial MRI.
Several previous MRI studies aimed to establish whether a speciﬁc
locations of lesions inMS patients is associatedwith the presence of mi-
graine. One study showed that MS patients with migraine had more le-
sions in red nucleus, substantia nigra and periaqueductal GM compared
to MS patients without migraine (Tortorella et al., 2006). Another study
conﬁrmed that MS patients who have midbrain plaques, in close prox-
imity to the periaqueductal GM have a four-fold increase in migraines
compared toMSpatientswithout plaques (Gee et al., 2005). These stud-
ies aimed to explain the onset of migraine symptoms by interruption of
circuits involved inmodulating pain pathways. As CE lesions rarely form
in those brain areas, the present study poses an alternative hypothesis
Table 4
Within disease course MRI comparisons between subjects with and without migraine.
RRMS
(n = 320)
SPMS
(n = 124)
PPMS
(n = 36)
W/o migraine
(n = 241)
Migraine
(n = 79)
p-Value W/o migraine
(n = 104)
Migraine
(n = 20)
p-Value W/o migraine
(n=30)
Migraine
(n = 6)
p-Value
Presence of CE
lesions
68 (28.2) 33 (41.8) 0.035 26 (25) 7 (35) 0.354 0 (0) 0 (0) NA
Number of CE
lesions
0.3 (0.84) 1.19 (4.9) 0.023 0.07 (.3) 0 (0) 0.224 0 (0) 0 (0) 0.806
CE-LV 41.1 (144.4) 164.4 (651.9) 0.02 6.1 (28.6) 0 (0) 0.324 1.6 (8.5) 0 (0) 0.806
Number of T2
lesions
27.1 (19.3) 28.2 (17.9) 0.951 33.8 (19.7) 29.4 (24.1) 0.241 31.8 (24.4) 15.3 (11.7) 0.081
T2-LV 11,421.3 (14,030.7) 12,163.3 (14,300) 0.732 19,357.2 (17,541.4) 19,850.3 (20,378.2) 0.701 17,256.3 (19,859.5) 10,457.4 (12,508.5) 0.413
Number of T1
lesions
10.1 (10.8) 9.7 (11.9) 0.638 15.1 (12.3) 12.4 (14.1) 0.352 11.6 (12.7) 11.3 (10.4) 0.98
T1-LV 2424.2 (4769.6) 3020.2 (8106.5) 0.417 5050.6 (7378.7) 4338.9 (6419.1) 0.580 2236.3 (2554.0) 2015.9 (2725.2) 0.850
NBV 1492.8 (88.5) 1488.8 (96.5) 0.187 1414.7 (77.4) 1428.5 (70.7) 0.832 1430.9 (93.9) 1485.9 (60.8) 0.688
NGMV 742.5 (66.3) 748.9 (64.7) 0.747 697.5 (58.9) 710 (54.5) 0.59 715.7 (48.4) 732.3 (57.5) 0.521
NWMV 750.3 (60.9) 740 (67.2) 0.144 717.2 (71.6) 718.6 (61.2) 0.825 715.3 (71.3) 753.6 (76.2) 0.423
NLVV 45.8 (20.1) 45.6 (22.8) 0.402 60.3 (22.7) 54.2 (23.6) 0.353 57 (26.8) 43 (8.8) 0.494
NCV 600.1 (55.5) 609.8 (52.7) 0.822 564.6 (50.9) 570 (41.8) 0.903 580.4 (41.9) 593.4 (55.3) 0.619
MS—multiple sclerosis; RRMS—relapsing–remitting; SPMS—secondary-progressive; PPMS—primary-progressive; SD—standard deviation; CE—contrast enhancing; LV—lesion volume;
NA—not available; NBV—normalized brain volume; NGMV—normalized gray matter volume; NWMV—normalized white matter volume; NLVV—normalized lateral ventricular volume;
NCV—normalized neocortical volume.
All data are presented asmean and standarddeviations. The presenceof CE is reported as the number and percentage. Volumetric calculations are presented in cubicmillimeters (mm3) for
LV and in cubic centimeters (cm3) for brain volumes.
The comparison between RRMS, SPMS and PPMS groups was performed using analysis of covariance with age, gender and disease-modifying treatment, as covariates. p-Values b 0.05
were considered signiﬁcant (highlighted in bold) after correction for multiple comparisons.
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lying widespread inﬂammatory process may be also an initial trigger in
some of the MS patients. It is also possible that these ﬁndings are not
mutually exclusive, and that both the lesion location and the inﬂamma-
tory process contribute to pain andmigraine onset. In line with a previ-
ous study (Kamson et al., 2012), we did not ﬁnd that MS patients or HIs
with and without migraine differed signiﬁcantly in T2 or T1 lesion bur-
den, although the RRMS patients with migraine in the present study
showed somewhat greater T2- and T1-LVs despite shorter disease dura-
tion compared to those without migraine.
Past studies have suggested that migraine is associated with GM pa-
thology (Rocca et al., 2006), although these ﬁndings were based on a
small number of subjects and there were other studies showing con-
ﬂicting results (Matharu et al., 2003). It has been demonstrated thatmi-
graine subjects do not present with cortical lesions (Absinta et al.,
2012). Brain volumetry ﬁndings from the current study suggest that
there is no signiﬁcant difference in the GM and WM in HIs, MS and
CIS groups between migraine and non-migraine subjects. Furthermore
we did not ﬁnd a signiﬁcant difference in GM volumes by MS disease
subtype. In terms of overall impact on MS severity, previous studies
have found no signiﬁcant correlation between level of disability and
the presence of headache (D3Amico et al., 2004), which was conﬁrmed
in the current study.
It has been shown that treatment ofMSwith interferon-beta is asso-
ciatedwith higher rate ofmigraine, but this increase ismainly due to the
exacerbation of preexisting migraine and is less commonly associated
with the new onset (Khromov et al., 2005; Villani et al., 2008; Villani
et al., 2012). This is further supported by the fact that patients receiving
interferon-beta may experience exacerbation of their migraine symp-
toms. As migraine may be iatrogenically triggered by use of DMT, we
used treatment status, as a covariate in all our analyses. We further ex-
plored the differences between interferon-beta and other DMTs in MS
patients with and without migraine (data not shown) and found no
associations.
In addition, neuropathic pain is frequent in patients with MS and
can be concomitantly present with migraine (Moisset et al., 2013).
In a recent study, 32% of the MS patients who presented both withmigraine and neuropathic pain, had more severe pain and lower
health-related quality of life than MS patients with either migraine or
neuropathic pain alone (Moisset et al., 2013). The pain intensity in
MS patients with migraine was higher (6.0 ± 0.1) than that of neuro-
pathic pain (4.9 ± 0.1). Moreover, in agreement with the present
study, the migraine MS patients were younger and had more likely
RRMS. This indicates that neuropathic pain and migraine pain may be
mediated by differentmechanisms and that optimal treatment forman-
agement of themigrainepain needsmore attention at individual patient
level.
There are several limitations to this study which warrant consider-
ation. Firstly, the timeline between the presentation ofmigraine and im-
aging was not well established, therefore it was not possible to assess
the correlation between MRI outcomes and frequency of migraine at-
tacks or migraine onset. This study utilized data from an ongoing pro-
spective study of cardiovascular, environmental and genetic risk
factors in clinically stable MS patients who performed their MRI within
30 days of entering the study. However, the proximity of the MRI to the
manifestation of migraine symptoms was consistent on an individual
basis, as we excluded MS patients with acute headache attack at the
time of MRI. Secondly, because subtype of migraine (migraine with
aura, etc) is difﬁcult to distinguish, and number of migraine attacks is
difﬁcult to capture retrospectively outside of specialty headache clinic,
we focused only on collecting information about diagnosis of migraine.
In addition, we did not apply most recent ICHD-3, which was not avail-
able at the timewhen this study was designed (Headache Classiﬁcation
Subcommittee of the International Headache Society, 2013). Thirdly,
the association of increased CE lesion activity in MS patients with mi-
graine does not prove causation, especially because we were not able
to apply a contrast agent to the HIs in this study, which prevented us
to understand whether migraine subjects without MS may show signs
of BBB disruption. Nevertheless, ﬁndings from current study should en-
courage further research using longitudinal design, to explore the oc-
currence of CE lesion activity in active and chronic migraine MS, CIS
and RIS subjects. Fourthly, the present study did not investigate the
onset of migraine symptoms by location of CE lesions and future studies
should investigate this topic. Finally, we did not investigate the onset of
116 E. Graziano et al. / NeuroImage: Clinical 9 (2015) 110–116migraine symptoms by location of CE lesions and future studies should
investigate this topic.
In conclusion, MS patients with migraine had a greater CE lesion ac-
tivity and this was speciﬁcally manifested in RRMS patients. Our ﬁnd-
ings suggest an increased inﬂammatory pathobiology in MS patients
with migraine headaches requiring possibly more frequent MRIs and
also more efﬁcient anti-inﬂammatory treatment.References
Absinta, M., et al., 2012. Patients with migraine do not have MRI-visible cortical lesions.
J. Neurol. 259 (12), 2695–2698. http://dx.doi.org/10.1007/s00415-012-6571-
x22714135.
Alroughani, R., et al., 2015. Status migrainosus as an initial presentation of multiple scle-
rosis. Springerplus 4, 28. http://dx.doi.org/10.1186/s40064-015-0818-925646151.
Benjamini, Y., et al., 2001. Controlling the false discovery rate in behavior genetics re-
search. Behav. Brain Res. 125 (1–2), 279–284. http://dx.doi.org/10.1016/S0166-
4328(01)00297-211682119.
Buzzi, M.G., et al., 1991. Dihydroergotamine and sumatriptan attenuate levels of CGRP in
plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal
ganglion. Neuropharmacology 30 (11), 1193–1200. http://dx.doi.org/10.1016/0028-
3908(91)90165-81663596.
D3Amico, D., et al., 2004. Prevalence of primary headaches in people with multiple sclero-
sis. Cephalalgia 24 (11), 980–984. http://dx.doi.org/10.1111/j.1468-2982.2004.
00790.x15482362.
Dolic, K., et al., 2011. Risk factors for chronic cerebrospinal venous insufﬁciency (CCSVI) in
a large cohort of volunteers. PLOS One 6 (11), e28062. http://dx.doi.org/10.1371/
journal.pone.002806222140507.
Elliott, D.G., 2007. Migraine in multiple sclerosis. Int. Rev. Neurobiol. 79, 281–302. http://
dx.doi.org/10.1016/S0074-7742(07)79012-817531846.
Ergün, U., et al., 2009. Headaches in the different phases of relapsing–remitting multiple
sclerosis: a tendency for stabbing headaches during relapses. Neurologist 15 (4),
212–216. http://dx.doi.org/10.1097/NRL.0b013e3181906fc919590381.
Gee, J.R., et al., 2005. The association of brainstem lesions withmigraine-like headache: an
imaging study of multiple sclerosis. Headache 45 (6), 670–677. http://dx.doi.org/10.
1111/j.1526-4610.2005.05136.x15953299.
Headache Classiﬁcation Subcommittee of the International Headache Society, 2013. The
International Classiﬁcation of Headache Disorders, 3rd edition (beta version).
Cephalalgia 33 (9), 629–808. http://dx.doi.org/10.1177/033310241348565823771276.
Headache Classiﬁcation Subcommittee of the International Headache Society, 2004. The
International Classiﬁcation of Headache Disorders: 2nd edition. Cephalalgia 24
(Suppl. 1), 9–16014979299.
Kamson, D.O., et al., 2012. Volumetric comparisons of supratentorial white matter
hyperintensities on FLAIR MRI in patients with migraine and multiple sclerosis. J. Clin.
Neurosci. 19 (5), 696–701. http://dx.doi.org/10.1016/j.jocn.2011.07.04422440862.
Kappos, L., et al., 1999. Predictive value of gadolinium-enhanced magnetic resonance im-
aging for relapse rate and changes in disability or impairment in multiple sclerosis: a
meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353 (9157), 964–969.
http://dx.doi.org/10.1016/S0140-6736(98)03053-010459905.
Kappus, N., et al., 2015. Cardiovascular risk factors are associated with increased lesion
burden and brain atrophy in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry
http://dx.doi.org/10.1136/jnnp-2014-31005125722366.
Karmon, Y., et al., 2012. Arterial, venous and other vascular risk factors in multiple sclero-
sis. Neurol. Res. 34 (8), 754–760. http://dx.doi.org/10.1179/1743132812Y.
000000007722971465.
Khromov, A., et al., 2005. Migraines linked to interferon-beta treatment of multiple scle-
rosis. Am. J. Phys. Med. Rehabil. 84 (8), 644–647. http://dx.doi.org/10.1097/01.phm.
0000171012.86932.1016034235.
Kister, I., et al., 2010. Migraine is comorbid with multiple sclerosis and associated with a
more symptomaticMS course. J. Headache Pain 11 (5), 417–425. http://dx.doi.org/10.
1007/s10194-010-0237-920625916.Lebrun, C., et al., 2008. Unexpected multiple sclerosis: follow-up of 30 patients with mag-
netic resonance imaging and clinical conversion proﬁle. J. Neurol. Neurosurg. Psychi-
atry 79 (2), 195–198. http://dx.doi.org/10.1136/jnnp.2006.10827418202208.
Lin, G.Y., et al., 2013. Multiple sclerosis presenting initially with a worsening of migraine
symptoms. J. Headache Pain 14, 70. http://dx.doi.org/10.1186/1129-2377-14-
7023937696.
Longoni, M., Ferrarese, C., 2006. Inﬂammation and excitotoxicity: role in migraine patho-
genesis. Neurol. Sci. 27 (Suppl. 2), S107–S110. http://dx.doi.org/10.1007/s10072-
006-0582-216688611.
Lucchinetti, C.F., et al., 2011. Inﬂammatory cortical demyelination in early multiple
sclerosis. N. Engl. J. Med. 365 (23), 2188–2197. http://dx.doi.org/10.1056/
NEJMoa110064822150037.
Matharu, M.S., et al., 2003. No change in the structure of the brain in migraine: a voxel-
based morphometric study. Eur. J. Neurol. 10 (1), 53–57. http://dx.doi.org/10.1046/
j.1468-1331.2003.00510.x12534993.
Moisset, X., et al., 2013. Migraine headaches and pain with neuropathic characteristics:
comorbid conditions in patients with multiple sclerosis. Pain 154 (12), 2691–2699.
http://dx.doi.org/10.1016/j.pain.2013.07.05023911697.
Nicoletti, A., et al., 2008. Headache and multiple sclerosis: a population-based case–
control study in Catania, Sicily. Cephalalgia 28 (11), 1163–1169. http://dx.doi.org/
10.1111/j.1468-2982.2008.01662.x18727645.
O3Connor, K., et al., 2012. Patterns of dietary and herbal supplement use by multiple
sclerosis patients. J. Neurol. 259 (4), 637–644. http://dx.doi.org/10.1007/s00415-
011-6226-321898138.
Okuda, D.T., et al., 2009. Incidental MRI anomalies suggestive of multiple sclerosis: the ra-
diologically isolated syndrome. Neurology 72 (9), 800–805. http://dx.doi.org/10.
1212/01.wnl.0000335764.14513.1a19073949.
Pakpoor, J., et al., 2012. Meta-analysis of the relationship between multiple sclerosis
and migraine. PLOS One 7 (9), e45295. http://dx.doi.org/10.1371/journal.pone.
004529523024814.
Putzki, N., et al., 2009. Prevalence of migraine, tension-type headache and trigeminal neu-
ralgia in multiple sclerosis. Eur. J. Neurol. 16 (2), 262–267. http://dx.doi.org/10.1111/
j.1468-1331.2008.02406.x19138330.
Rocca, M.A., et al., 2006. Brain gray matter changes in migraine patients with T2-visible
lesions: a 3-T MRI study. Stroke 37 (7), 1765–1770. http://dx.doi.org/10.1161/01.
STR.0000226589.00599.4d16728687.
Samkoff, L.M., Goodman, A.D., 2011. Symptomatic management in multiple sclerosis.
Neurol. Clin. 29 (2), 449–463. http://dx.doi.org/10.1016/j.ncl.2011.01.00821439453.
Silberstein, S.D., 2004. Migraine pathophysiology and its clinical implications. Cephalalgia
24 (Suppl. 2), 2–7. http://dx.doi.org/10.1111/j.1468-2982.2004.00892.x15595988.
Smith, S.M., et al., 2002. Accurate, robust, and automated longitudinal and cross-sectional
brain change analysis. Neuroimage 17 (1), 479–489. http://dx.doi.org/10.1006/nimg.
2002.104012482100.
Tortorella, P., et al., 2006. Assessment ofMRI abnormalities of the brainstem from patients
with migraine and multiple sclerosis. J. Neurol. Sci. 244 (1–2), 137–141. http://dx.doi.
org/10.1016/j.jns.2006.01.01516530789.
Vacca, G., et al., 2007. Multiple sclerosis and headache co-morbidity. A case–control study.
Neurol. Sci. 28 (3), 133–135. http://dx.doi.org/10.1007/s10072-007-0805-117603764.
Villani, V., et al., 2008. Primary headache and multiple sclerosis: preliminary results of a
prospective study. Neurol. Sci. 29 (Suppl. 1), S146–S148. http://dx.doi.org/10.1007/
s10072-008-0908-318545918.
Villani, V., et al., 2012. The impact of interferon beta and natalizumab on comorbid
migraine in multiple sclerosis. Headache 52 (7), 1130–1135. http://dx.doi.org/10.
1111/j.1526-4610.2012.02146.x22486199.
Watkins, S.M., Espir, M., 1969. Migraine and multiple sclerosis. J. Neurol. Neurosurg.
Psychiatry 32 (1), 35–37. http://dx.doi.org/10.1136/jnnp.32.1.355774132.
Zivadinov, R., et al., 2011. Prevalence, sensitivity, and speciﬁcity of chronic cerebrospinal
venous insufﬁciency in MS. Neurol. 77 (2), 138–144. http://dx.doi.org/10.1212/WNL.
0b013e318212a90121490322.
Zivadinov, R., et al., 2012. Abnormal subcortical deep-gray matter susceptibility-weighted
imaging ﬁltered phase measurements in patients with multiple sclerosis: a case–
control study. Neuroimage 59 (1), 331–339. http://dx.doi.org/10.1016/j.neuroimage.
2011.07.04521820063.
Zorzon, M., et al., 2003. Risk factors of multiple sclerosis: a case–control study. Neurol. Sci.
24 (4), 242–247. http://dx.doi.org/10.1007/s10072-003-0147-614658040.
